Advertisement

Antibiotics pp 29-49 | Cite as

The FDA

  • David M. ShlaesEmail author
Chapter

Abstract

It is clear that we need a viable, strong, active and even interventionist FDA. But we also need new antibiotics. How did we get to a place where these two obvious needs might be in conflict?

Keywords

Advisory Committee Clinical Trial Design Infectious Disease Society Infectious Disease Physician Acute Bacterial Sinusitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  1. 1.Anti-infectives Consulting, LLCStoningtonUSA

Personalised recommendations